Halfway through 2018, MariMed already ranked as the top-performing marijuana stock of all. Its winning ways continued in the second half of the year despite a marked decline over the last couple of months. MariMed is set to finish 2018 up more than 300%.
The company’s revenue soared in 2018, with $8.4 million made in the first nine months of the year — an 88% year-over-year jump. MariMed’s operations now span six states that have legalized medical marijuana, with two of them also legalizing recreational marijuana.
MariMed first made its name by providing advisory services to businesses operating in the U.S. cannabis industry. But the company eventually decided that it would rather run businesses than only serve as consultants to them. As a result, MariMed began acquiring its customers. The company has also made other deals, notably including a strategic investment in hemp-based CBD company GenCanna.
Read the entire original article here.